All In Biotech

Drug Trial Radar · NCT01139216

Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation

Effect of DAIKENCHUTO (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Female Patients With Functional Constipation

Last checked: Nov 19, 2026Latest source record: Jan 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Aug 2010

Primary completion

Nov 2012

Study completion Nov 2012

Sponsor

Lead sponsor
Tsumura USAIndustry
Sponsor type
Industry
Collaborators
Cato Research
First posted
Jun 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the dose-related effects of TU-100, a botanical agent that modulates gastrointestinal nerves, on rectal compliance, rectal sensation thresholds and small bowel and colonic transit in female patients with functional constipation as compared to placebo.

Conditions

  • Functional Constipation
  • Gastric Emptying
  • Whole Gut Transit
  • Small Bowel Transit
  • Colonic Transit
  • Rectal Compliance
  • Rectal Sensation

Interventions

  • Daikenchuto (TU-100)Drug

    Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.

  • Daikenchuto (TU-100)Drug

    Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.

  • PlaceboDrug

    Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Colonic geometric center at 24 hours measured by scintigraphyTime frame: Up to 48 hours
  2. T1/2 of ascending colon emptying as measured by scintigraphyTime frame: Up to 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic, Rochester Methodist CRU

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.